Research & development
| Development Code / Nonproprietary Name | Classification | Indications | Development Phase | |
|---|---|---|---|---|
 | ||||
| Pitavastatin | HMG-CoA reductase inhibitor | Dyslipidemia |  |  |
| Ripasudil | Rho kinase inhibitor | Glaucoma and ocular hypertension Fuchs endothelial corneal dystrophy |  | |
| Pemafibrate | Selective PPARα modulator | Dyslipidemia Primary biliary cholangitis |  |  |
| Pemafibrate/ Tofogliflozin | Selective PPARα modulator/ SGLT2 inhibitor | Non-alcoholic steatohepatitis | | |
| K-161 | Dry eye disease | | ||
 |
Key products undergoing investigation in Europe as part of a global research program are:
Ripasudil
Pipeline
Notes
- Only a product in Clinical Stage is listed. This list does not include all of the products.
- A product in Clinical Stage is defined as a product for which a regulatory procedure has been made for initiation of a first clinical trial (i.e. Investigational New Drug application in US, Clinical Trial Application in Europe, Clinical Trial Notification in Japan, or a similar process in other regions) and a regulatory procedure for discontinuation of development has not been made or regulatory approval has not been obtained in any regions where approval is anticipated.
- A product assigned with International Nonproprietary Name (INN) is listed as its nonproprietary name. Otherwise, a development code is used.
- This list shows the most advanced development phase for a product which is in more than one phase amongst countries and/or regions. In addition, countries and regions where regulatory application for marketing authorization (e.g. New Drug Application in US) has been filed with an approval yet to be granted, are also listed.
- This list also includes a product in Clinical Stage for new indication(s) even if it has been already approved for different indication(s).
For more information on our research and development program visit https://www.kowa.co.jp/eng/business/health/development.html